[Jean]

First of all the first post I made about the study was from breastcancer.org and the source was from the Journelof Oncology...2007.
The findings stem from an analysis of data for women diagnosed with breast cancer from 1992 to 2002 and entered in a Medicare-linked database. So it is not based on 70's 80's and 90's. When I posted those yrs. it was only to state about another study which was done in France during those dates.

So therefore the percentages that were first stated in the first post are newer studies, I only replied to Hopefully that studies were being done as far back as those years.

The important issue is that in the studies from 1992 to 2002 decisions regarding adjuvant chemotherapy in older women must incorporate both short- and long-term risks of chemotherapy as well as potential benefits, so that patients can make informed decisions.

The study for the period of 1992-2002 did not mention the stage of cancer or for that matter who was HER2.
The time line from 1992 - 2002 I would think would be a greater issue for those dx with HER2 before use of
hercpetin was protocal. (I believe you had to be stage IV to have herceptin as a treatment).

While the study does NOT demonstrate how many were dx. with HER2 it is still prudent to say that HER2 at any stage is a serious threat. So - with that in mind I repeat again that when being dx. HER2 each woman has to make their own choices about risk of treatment.
The study of 1996-2002 deomonstrates that the risk
holds a slight difference from those who received chemo/and those who did not.